http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114767844-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed332943863712db2d3245b3e15320ed |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate | 2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114767844-A |
| titleOfInvention | A kind of varicella-zoster virus vaccine and its application |
| abstract | The invention provides a varicella-zoster virus vaccine and application thereof, belonging to the technical field of vaccines; the varicella-zoster virus vaccine comprises liposome nanoparticles and liposome nanoparticles encapsulated in the liposome nanoparticles Herpes zoster virus glycoprotein E and an adjuvant; the adjuvant includes a triterpenoid saponin. In the present invention, after the herpes zoster virus glycoprotein E (gE) is encapsulated by liposome nanoparticles, it can effectively promote the phagocytosis of antigen-presenting cells and efficiently deliver antigens, and realize the sustained release of the vaccine and continuously stimulate the body to produce VZV-gE specific cellular immune response. The triterpenoid saponins used in the invention can effectively realize the cross-presentation of the antigenic herpes zoster virus glycoprotein E and induce antigen-specific cellular immune responses. Moreover, the cholesterol rich in lipid nanoparticles can effectively neutralize the cytotoxicity of triterpenoid saponins, ensuring the safety of the vaccine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116023510-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116023510-B |
| priorityDate | 2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 168.